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Abstract.	
	
The	 objective	 of	 the	 research	was	 to	 assess	 risk	 factors	 for	 precancerous	
gynecological	 disease	 (PGD)	 in	 patients	 with	 breast	 cancer	 (BC)	 after	
comprehensive	and	combination	treatment.	
Materials	and	methods.	The	study	was	based	on	the	results	of	examination	
and	 treatment	 of	 40	patients	 suffering	 from	BC	with	 PGD	which	developed	 at	
different	 times	 after	 treatment.	 In	 patients	 with	 breast	 cancer	 PGD	 included	
precancerous	 uterine	 body	 disease	 in	 26	 (65.0	 %)	 patients,	 the	 precancerous	
ovariopathies	 in	 9	 (22.5	 %)	 individuals	 and	 precancerous	 cervical	 disease	 in	 5	
(12.5%)	cases.	
Results	of	 the	research.	Precancerous	uterine	body	disease	occurred	most	
often	in	most	patients	with	BC	after	treatment.	It	included	atypical	endometrial	
hyperplasia	 in	 19	 (73.0%)	 patients	 and	 proliferating	 nodular	 leiomyoma	 of	
uterine	body	in	7	(27.0%)	cases.	Precancerous	ovariopathies	detected	in	patients	
with	BC	included	allied	papillary	mucinous	cystadenoma	of	ovaries	in	6	(66.7%)	
patients	and	endometrioid	cystadenoma	in	3	(33.3%)	cases.	Precancerous	cervical	
disease	 detected	 in	 patients	 with	 BC	 included	 severe	 cervical	 intraepithelial	
neoplasia	(CIN	III).	CIN	III	was	found	in	5	(12.5%)	cases.		
Conclusions.	According	 to	 the	 results	of	 the	analysis	and	 literature	data,	
PGD	occurred	 in	patients	with	BC.	The	results	 indicated	 that	hormonal	 factors,	
burdened	 oncology	 case	 history	 and	 results	 of	 immunohistochemical	 and	
molecular	genetic	diagnosis	of	breast	tumors	are	important	in	PGD	development	
in	patients	with	BC.	
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Problem	statement	and	analysis	of	the	recent	research	
Breast	cancer	 (BC)	takes	the	 lead	 in	the	structure	of	cancer	 incidence	and	mortality	of	the	
female	population	of	Ukraine	and	most	economically	developed	countries.	According	to	National	
Cancer	Registry,	the	incidence	of	breast	cancer	in	Ukraine	in	2013	constituted	72.3	per	100	thousand	
and	 mortality	 amounted	 31.6	 per	 100	 thousand	 female	 population.	 37%	 of	 patients	 with	 breast	
cancer	are	women	of	 reproductive	and	working	age	 [1].	5-year	survival	 index	of	breast	cancer	 in	
Ukraine	(2013)	was	53.8%	while	it	constituted	75-80	%	in	Western	Europe	countries	and	85-92%	in	
the	USA	[1,	2].	
Breast	cancer	refers	to	hormone-related	and	hormone	dependent	tumors	as	well	as	ovarian	
tumor	 and	 tumor	 of	uterus.	 Latent	 or	distinct	 chronic	hyperestrogenemia	 is	 the	main	 common	
factor	for	all	the	above	mentioned	tumors	except	metabolic	factors	[3,	4].	This	indicates	that	breast	
cancer	is	a	systemic	disease	[5,	6].		
Cases	 of	 precancerous	 gynecological	 diseases	 (PGD)	 in	 patients	 with	 breast	 cancer	 have	
been	increasingly	detected	over	the	last	decades.	The	absence	of	downward	trend	in	the	incidence	
of	reproductive	system	diseases	 in	women	 justifies	the	 increased	attention	to	this	problem.	New	
programs	aimed	at	prevention	and	early	diagnosis	of	cancer	tumors	including	ovarian	tumor	and	
tumor	of	uterus	 in	patients	with	breast	cancer	are	 required	 for	 the	solution	of	 the	problem.	PGD	
development	 belongs	 to	 poorly	 studied	 diseases	 although	 the	 interest	 in	 them	 appeared	 in	 the	
1970s.	 Scientific	 research	 on	 PGD	 clinical	 features	 and	 course	 was	 presented	 in	 a	 number	 of	
monographs	and	articles	[7,	8].	
Results	 of	 the	 clinical	 studies	 indicate	 the	 increase	 in	 PGD	 incidence	 in	 the	 recent	 years	
which	can	be	explained	by	several	 factors.	First	of	all,	 this	may	occur	due	 to	 the	optimization	of	
tumor	 diagnostics	 by	 introduction	 of	 new	 methods	 of	 patients’	 examination	 (endoscopy	 and	
ultrasonic	 diagnosis,	 computed	 tomography	 and	 magnetic	 resonance	 imaging,	
immunoenzymometric,	immunomorphologic	and	molecular	genetic	methods	of	surgical	specimen	
research).	 In	addition,	PGD	development	 in	patients	with	BC	 is	possible	after	treatment	of	cancer	
patients,	especially	young	patients,	using	chemotherapy	and	radiotherapy	which	are	characterized	
by	 mutagenic	 effect	 on	 cells.	 Harmful	 environmental	 factors,	 working	 conditions,	
immunodeficiency,	and	lifestyle	are	also	a	precondition	for	the	development	of	this	disease	[9,	10].	
	However,	despite	 the	 long-time	 studies,	 their	 comprehensive	 clinical	 characterization	 is	
still	absent	due	 to	 the	variety	of	histological	 types,	principles	of	 their	prevention	have	not	been	
developed	 yet,	 approaches	 to	 patients’	 monitoring	 have	 not	 been	 determined,	 risk	 groups	
concerning	 PGD	 development	 after	 treatment	 of	 patients	 with	 breast	 cancer	 have	 not	 been	
selected.		
The	 objective	 of	 the	 research	 was	 to	 assess	 risk	 factors	 for	 precancerous	 gynecological	
disease	in	patients	with	breast	cancer	after	comprehensive	and	combination	treatment.	
	
Materials	and	methods	of	the	research	
The	study	was	based	on	the	results	of	examination	and	treatment	of	40	patients	suffering	
from	BC	with	PGD	which	developed	at	different	times	after	treatment.	All	the	patients	were	treated	
at	Ivano-Frankivsk	Regional	Clinical	Oncology	Center	from	1996	to	2015.		
The	age	of	patients	with	BC	involved	into	the	studies	ranged	from	31	to	76	years,	the	average	
age	was	47.3±1.7.		
In	patients	suffering	from	BC	with	PGD	BC	stage	II	was	detected	in	18	(45.0	%)	patients,	BC	
stage	 I	was	observed	 in	11	 (27.5	%)	patients,	BC	stage	 III	was	 found	 in	10	 (25.0	%)	 individuals,	BC	
stage	IV	was	detected	in	1	(2.5	%)	patient.		
According	 to	 the	 results	 of	 histologic	 examination	 of	 biopsy	 and	 surgical	 specimen	
infiltrating	 breast	 carcinoma	 was	 verified	 in	 33	 (82.5%)	 patients,	 intraductal	 noninfiltrating	
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carcinoma	 was	 detected	 in	 3	 (7.5	 %)	 cases	 and	 mucinous	 carcinoma	 was	 observed	 in	 2	 (5.0	 %)	
patients.		
In	all	these	patients	with	breast	cancer	PGD	occurred	including	precancerous	uterine	body	
disease	 in	 26	 (65.0	 %)	 patients,	 the	 precancerous	 ovariopathies	 in	 9	 (22.5	 %)	 individuals	 and	
precancerous	cervical	disease	in	5	(12.5%)	cases.	
Variational	and	statistical	analysis	was	applied	to	assess	the	reliability	of	the	results	using	
a	 personal	 computer	 and	 such	 applications	 as	 Microsoft®	Office	 Excel®	2007	 and	 Statistica	 v.6.1	
(Statsoft	Inc.,	USA).	The	database	was	formed	on	the	basis	of	Ms	Excel	tables.		
	
Results	of	the	research	and	their	discussion	
Precancerous	uterine	body	disease	 (PUBD)	occurred	most	often	 in	most	patients	with	BC	
after	 treatment.	PUBD	 in	patients	with	BC	was	detected	 in	26	 (65.0	%).	PUBD	 in	patients	with	BC	
included	atypical	endometrial	hyperplasia	and	proliferating	nodular	 leiomyoma	of	uterine	body.	
Atypical	 endometrial	 hyperplasia	 was	 detected	 more	 often,	 namely	 in	 19	 (73.0%)	 patients	 and	
proliferating	nodular	leiomyoma	of	uterine	body	was	diagnosed	in	7	(27.0%)	cases.		
Patients’	age	ranged	between	38	and	77	years	at	the	time	of	PUBD	onset.		
	
	
Fig	1.	Distribution	of	patients	who	experienced	PUBD	after	breast	cancer	treatment	by	age	
groups		
	
The	 largest	number	of	patients	with	PUBD	was	observed	 in	 the	age	group	of	50-59	years,	
namely	11	(42.3%)	patients.	The	age	group	of	30-39	years	included	1	(3.9	%)	patient.	The	age	group	
of	 40-49	 years	 consisted	 of	 7	 (26.9	%)	 patients.	Older	 age	 groups	 of	 60-69	 years	 and	 70-79	 years	
included	5	(19.2%)	and	2	(7.7%)	patients	respectively.		
	Burdened	 oncology	 case	 history	 was	 detected	 in	 14	 (57	 %)	 patients	 with	 PUBD.	 Two	
pregnancies	occurred	10	(38.5	%)	patients	with	PUBD,	one	pregnancy	occurred	in	7	(26.9	%)	women,	
3	and	more	pregnancies	occurred	in	8	(30.7	%)	patients	with	PUBD.	1	(3.9%)	patient	was	with	primary	
infertility.		
Analyzing	menopause	onset	in	women	with	PUBD	premature	menopause	(before	the	age	of	
45)	was	detected	in	8	(30.8	%)	patients	and	late	menopause	(after	the	age	of	55)	was	observed	in	4	
(15.4%)	women.	Natural	menopause	occurred	in	14	(53.8	%)	cases.		
Immunohistochemical	tumor	status	was	also	determined.	Luminal	A	type	(ER+	and/or	RP+,	
HER2neu-)	was	determined	 in	15	 (57.7	%)	cases;	 luminal	B	 type	 (ER+	and/or	RP+,	HER2	neu+)	was	
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detected	 in	 5	 (19.2	 %)	 patients;	 triple	 negative	 one	 (ER-,	 RP-,	 HER2neu-)	 was	 found	 in	 2	 (7.7	 %)	
women.		
Concomitant	diseases	diagnosed	 in	patients	with	PUBD	 included	cardio-vascular	diseases	
in	21	(80.8	%)	cases,	endocrine	diseases	in	13	(50.0	%)	patients,	namely	diabetes	mellitus	in	7	(53.8	
%)	patients	and	nodular	goiter	in	6	(46.2	%)	patients.	Overweight	was	detected	in	12	(46.2	%)	cases.		
Surgical	treatment,	namely	oophorohysterectomy	type	I,	was	conducted	to	all	patients	with	
PUBD.	
Proliferating	nodular	 leiomyoma	of	uterine	body	was	diagnosed	 in	8	months	after	the	end	
of	BC	treatment	when	rapid	growth	of	the	uterine	body	tumor	was	observed.	Atypical	endometrial	
hyperplasia	occurred	in	23	months.		
Precancerous	ovariopathies	rank	second	after	PUBD	among	gynecological	pathology.	Allied	
papillary	 mucinous	 cystadenoma	 of	 ovaries	 and	 endometrioid	 cystadenoma	 were	 detected	 in	
patients	 with	 precancerous	 ovariopathies.	 Precancerous	 ovariopathies	 were	 found	 in	 9	 (22.5	 %)	
patients.	Allied	papillary	mucinous	cystadenoma	of	ovaries	was	diagnosed	in	6	(66.7	%)	cases	and	
endometrioid	cystadenoma	was	detected	in	3	(33.3	%)	women.	
The	average	age	of	patient	with	precancerous	ovariopathies	ranged	from	32	to	80	years.		
3	(33.3	%)	and	4	(44.5	%)	patients	with	precancerous	ovariopathies	were	observed	in	the	age	
groups	of	30-39	years	and	40-49	years	respectively.	One	patient	was	observed	 in	the	age	group	of	
50-59	years	and	one	in	the	age	group	of	80-89	years.		
	
	
Fig	 2.	 Distribution	 of	 patients	 who	 experienced	 precancerous	 ovariopathies	 after	 breast	
cancer	treatment	by	age	groups	
	
Burdened	 oncology	 case	 history	 was	 detected	 in	 7	 (77.8	 %)	 patients	 with	 precancerous	
ovariopathies.	Thus,	burdened	oncology	case	history	was	a	 factor	of	precancerous	ovariopathies	
development	 in	 patients	 with	 BC.	 3	 and	 more	 pregnancies	 occurred	 in	 5	 (55.6	 %)	 patients	 with	
precancerous	ovariopathies.	Primary	infertility	was	detected	in	2	(22.2%)	women.		
Depending	 on	 menopause	 onset	 time	 premature	 menopause	 was	 detected	 in	 5	 (55.6	 %)	
cases	and	late	and	natural	menopause	occurred	in	2	(22.2	%)	patients	respectively.	
The	 most	 common	 concomitant	 diseases	 included	 cardiovascular	 disease	 in	 8	 (88.9	 %)	
patients,	metabolic	syndrome	in	6	(66.7	%)	cases	and	gastrointestinal	diseases	in	4	(44.4	%)	women.		
Cancer-specific	 marker	 СА-125	 was	 determined	 in	 all	 patients	 with	 precancerous	
ovariopathies.	СА-125	index	was	above	normal	level	in	3	(33.3	%)	patients,	mean	value	constituted	
32.55	IU/ml,	maximum	value	amounted	157.1	IU/ml.		
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According	 to	 immunohistochemical	 and	 molecular	 genetic	 classification	 of	 tumor	 types,	
basal	type	was	detected	in	5	(55.6	%)	patients	with	precancerous	ovariopathies,	luminal	type	A	was	
observed	in	1	(11.1%)	patient	and	triple	negative	type	was	detected	in	1	patient	as	well	(11.1%).		
Surgical	treatment	was	performed	to	all	patients	with	precancerous	ovariopathies.	Bilateral	
adnexectomy	 was	 performed	 in	 4	 (44.4	 %)	 cases.	 5	 (55.6%)	 patients	 underwent	
oophorohysterectomy	with	omentum	resection.		
Precancerous	ovariopathies	occurred	 in	all	patients	 in	about	 the	same	 time,	namely	 in	68	
months,	after	the	end	of	BC	treatment.		
According	 to	 precancerous	 ovariopathies	 analysis	 in	 patients	 with	 BC	 such	 factors	 as	
burdened	 oncology	 case	 history,	 primary	 infertility,	 and	 premature	 menopause	 were	 detected.	
Determining	 the	 receptor	 status	 of	 breast	 tumors	 in	 patients	 with	 precancerous	 ovariopathies,	
basal	type	was	detected.	Its	prognosis	for	treatment	is	negative.		
We	 analyzed	 the	 onset	 of	 precancerous	 cervical	 disease	 (PCD)	 after	 BC	 treatment.	
Precancerous	cervical	disease	detected	in	patients	with	BC	included	severe	cervical	intraepithelial	
neoplasia	(CIN	III)	in	5	(12.5%)	cases.		
The	 age	 of	 patients	 with	 PCD	 ranged	 from	 36	 to	 48	 years.	 The	 age	 group	 of	 30-39	 years	
included	2	(40	%)	patients	with	PCD	and	the	age	group	of	40-49	years	consisted	of	3	(60	%)	women.		
Cervical	 diathermic	 electro-conization	 with	 the	 following	 cryolysis	 was	 conducted	 to	
patients	with	CIN	III.	CIN	III	occurred	in	50	months	after	the	end	of	BC	treatment.		
Thus,	 taking	 into	 account	 the	 incidence	 of	 severe	 cervical	 intraepithelial	 neoplasia	 in	
patients	with	BC,	 regular	cervical	cytological	examination	during	periodic	health	examination	of	
the	patient	concerning	BC	was	shown.		
	
Conclusions	
According	to	the	results	of	the	analysis	and	literature	data	patients	with	BC	are	at	high	risk	
of	PGD	development.	The	obtained	results	 indicated	that	hormonal	factors	 (primary	 infertility,	or	
3	 and	 more	 pregnancies,	 violation	 of	 early	 menopause	 onset,	 concomitant	 endocrine	 diseases),	
burdened	 oncology	 case	 history	 and	 results	 of	 immunohistochemical	 and	 molecular	 genetic	
diagnosis	 of	 breast	 tumors	 (luminal	 type	 A,	 basal	 type)	 are	 important	 in	 PGD	 development	 in	
patients	with	BC.	Therefore,	there	is	a	need	for	better	detalization	of	clinical	anamnestic	data	when	
examining	patients	with	breast	cancer	and	a	comparison	of	clinical,	endocrinologic,	clinical	and	
genealogical	and	pathological	features	of	breast	cancer	and	PGD.	This	can	become	the	basis	for	PGD	
risk	calculations.		
	
Prospects	for	further	research	
Creating	 risk	 factors	 programs	 aimed	 at	 prevention	 and	 early	 detection	 of	 precancerous	
gynecologic	 neoplasms	 in	 patients	 with	 breast	 cancer	 will	 prevent	 the	 development	 of	
metachronous	malignant	tumors.	
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